THE INCREASING use of chlorpromazine (CPZ) has led to an increasing awareness of its potential ability to cause agranulocytosis 1-4 and the studies of Pisciotta and his co-workers have led to a better understanding of the mechanisms by which this toxic effect is produced.5-8 By contrast, anemia, either hemolytic 9,10 or aplastic, is a much rarer manifestation of the potential bone marrow toxicity of this agent. Aplastic anemia with pancytopenia has been reported in one case by Shelton et al 11 and a total of 24 cases of this type of anemia following the administration of CPZ has been reported to the AMA Council on Drug Reactions.12
The mechanisms by which this drug might produce anemia have not been studied. It would seem unlikely that the abnormalities of deoxyribonucleic acid synthesis in leukocytes resulting from CPZ administration described by Pisciotta et al would only affect the single
MANSOUR N, BROUN GO. Depression of Erythropoiesis Associated With Chlorpromazine Therapy. Arch Intern Med. 1967;119(1):113–116. doi:10.1001/archinte.1967.00290190161018
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: